Calyxt

Calyxt, Inc. is technology company. engages in delivering plant-based solutions. Its products include high oleic soybean oil, high fiber wheat, high oleic soybean meal, and low lignin alfalfa. The company was founded by Daniel F. Voytas and André Choulika on January 8, 2010 and is headquartered in Roseville, MN.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. It focuses on using gene editing to develop productivity traits in major agricultural crops such as Canola, Rice, Soybean, Corn and Wheat. The company was founded by Rory Riggs, Peter Beetham and Greg Gocal in 2010 and is headquartered in San Diego, CA.

Agreement will power speed-to-scale strategy to meet the growing interest in high-quality sustainable ingredients across the cosmeceutical, nutraceutical and pharmaceutical markets ROSEVILLE, Minn. , Oct. 6, 2022 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that it has signed an agreement with its first manufacturing partner, Evologic Technologies GmbH, to further develop and scale Calyxt's proprietary Plant Cell Matrix™ (PCM™) technology platform.

Calyxt Announces Agreement with Evologic Technologies to Scale Production of its Plant-based Ingredients

ROSEVILLE, Minn. , Sept. 22, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT) ("Calyxt"), a plant-based synthetic biology company, today announced that its Board of Directors is evaluating potential strategic alternatives to maximize shareholder value.

Calyxt, Inc. Exploring Strategic Alternatives

ROSEVILLE, Minn. , Sept. 7, 2022 /PRNewswire/ -- Calyxt, Inc.  (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that Michael A.

Calyxt to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Calyxt (CLXT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Bears are Losing Control Over Calyxt (CLXT), Here's Why It's a 'Buy' Now

Calyxt, Inc. (NASDAQ:CLXT ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Bill Koschak - Chief Financial Officer Michael Carr - President and Chief Executive Officer Conference Call Participants Bobby Burleson - Canaccord Amit Dayal - H.C. Wainwright Brian Wright - ROTH Capital Partners Operator Good afternoon, ladies and gentlemen.

Calyxt, Inc. (CLXT) CEO Michael Carr on Q2 2022 Results - Earnings Call Transcript

Calyxt (CLXT) delivered earnings and revenue surprises of 6.67% and 36.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Calyxt (CLXT) Reports Q2 Loss, Tops Revenue Estimates

Evaluated nine new customer demand-driven plant-based chemistries in the quarter, bringing cumulative chemistries evaluated for development to 95, of these 31 meet Calyxt's target profile and several are the subject of term sheet discussions Engineering solution for a high-value molecule planned to be delivered in early 2023 to a large global consumer packaged goods company Progressing discussions with multiple potential infrastructure partners who would produce chemistries in various sizes of bioreactors from pilot to commercial scale Evaluating term sheets for technology licensing and for licensing of traits Management to host conference call and webcast today at 4:30 p.m. ET ROSEVILLE, Minn.

Calyxt Reports Second Quarter 2022 Financial Results and Provides Corporate Update

ROSEVILLE, Minn. , July 28, 2022 /PRNewswire/ --  Calyxt, Inc.  (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that Michael A.

Calyxt to Present at the Canaccord Genuity 42nd Annual Growth Conference

ROSEVILLE, Minn. , July 21, 2022 /PRNewswire/ --   Calyxt, Inc.  (Nasdaq: CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, August 4, 2022, at 4:30 p.m.

Calyxt to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time

ROSEVILLE, Minn. , May 17, 2022 /PRNewswire/ -- Calyxt , Inc.  (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that management will participate in the following upcoming investor conferences: H.C.

Calyxt to Present at Upcoming Conferences

Calyxt, Inc. (NASDAQ:CLXT ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Bill Koschak - Chief Financial Officer Michael Carr - President and Chief Executive Officer Conference Call Participants Bobby Burleson - Canaccord Amit Dayal - H.C. Wainwright Brian Wright - ROTH Capital Partners Operator Good afternoon, ladies and gentlemen.

Calyxt, Inc. (CLXT) CEO Michael Carr on Q1 2022 Results - Earnings Call Transcript

Calyxt (CLXT) delivered earnings and revenue surprises of 22.22% and 96.24%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Calyxt (CLXT) Reports Q1 Loss, Misses Revenue Estimates

Achieved technical BioFactory™ and AIML milestones to support customer demand-driven molecule development at scale Progressed relationships with an expanding network of potential new customers across the cosmeceutical and flavor and fragrance end markets Continued investment in key hires to strategically position Company for future growth and scale Management to host conference call and webcast today at 4:30 p.m. ET ROSEVILLE, Minn.

Calyxt Reports First Quarter 2022 Financial Results

Continued investment in key hires to strategically position Company for future growth and scale ROSEVILLE, Minn. , April 26, 2022 /PRNewswire/ -- Calyxt, Inc.  (Nasdaq: CLXT), a plant-based synthetic biotechnology company, yesterday welcomed the second of two director-level hires in areas critical to the continued advancement of the Company's key technology and business development goals.

Calyxt Announces Strategic Hires in Business Development and Manufacturing

ROSEVILLE, Minn. , April 21, 2022 /PRNewswire/ -- Calyxt, Inc.  (Nasdaq: CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, May 5, 2022, at 4:30 p.m.

Calyxt to Host First Quarter 2022 Financial Results Conference Call and Webcast on Thursday, May 5, 2022, at 4:30 p.m. Eastern Time

Calyxt is now on to its third business plan, pivoting from gene-edited seed traits to synthetic biology. The company is looking to produce molecules of interest to pharmaceutical, nutraceutical, and cosmeceutical companies through sustainable plant-based technology.

Calyxt Switches Gears Again, But The Cash Clock Keeps Ticking Down

ROSEVILLE, Minn., March 8, 2022 /PRNewswire/ --  Calyxt, Inc.  (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that management will participate in a fireside chat at the 34th Annual Roth Conference at the Ritz-Carlton in Dana Point, CA.

Calyxt to Participate in Fireside Chat at the 34th Annual Roth Conference

Calyxt, Inc.'s (CLXT) CEO Michael Carr on Q4 2021 Results - Earnings Call Transcript

Calyxt (CLXT) delivered earnings and revenue surprises of 17.39% and 42.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Calyxt (CLXT) Reports Q4 Loss, Misses Revenue Estimates

ROSEVILLE, Minn., March 3, 2022 /PRNewswire/ --  Calyxt, Inc.  (Nasdaq: CLXT), a plant-based synthetic biology company, today announced financial results for its fourth quarter and full year ended December 31, 2021.

Calyxt Reports Fourth Quarter and Full Year 2021 Financial Results

ROSEVILLE, Minn., Feb. 24, 2022 /PRNewswire/ --  Calyxt, Inc.  (Nasdaq: CLXT), a plant-based synthetic biology company, will hold a conference call on Thursday, March 3, 2022, at 4:30 p.m.

Calyxt to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Thursday, March 3, 2022, at 4:30 p.m. Eastern Time

ROSEVILLE, Minn., Feb. 23, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT) ("Calyxt" or the "Company"), a plant-based synthetic biology company, today announced the closing of its previously announced placement to an institutional investor in an underwritten offering of 3,880,000 shares of its common stock, pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and common warrants to purchase up to 7,760,000 shares of its common stock (the "Offering").

Calyxt Announces Closing of SEC-Registered Offering of Common Stock, Pre-Funded Warrants to Purchase Common Stock and Warrants to Purchase Common Stock

ROSEVILLE, Minn., Feb. 17, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT) ("Calyxt" or the "Company"), a plant-based synthetic biology company, today announced the placement to an institutional investor in an underwritten offering of 3,880,000 shares of its common stock, pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and common warrants to purchase up to 7,760,000 shares of its common stock (the "Offering").

Calxyt, Inc. Announces Pricing of $10.9 Million SEC-Registered Offering of Common Stock and Warrants

ROSEVILLE, Minn., Feb. 7, 2022 /PRNewswire/ --  Calyxt, Inc.  (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced that Gerry Nuovo has joined Calyxt as Senior Vice President of Business Development.

Calyxt Announces Gerry Nuovo as Senior Vice President of Business Development

ROSEVILLE, Minn., Jan. 6, 2022 /PRNewswire/ --  Calyxt, Inc.  (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced that its pilot BioFactory™ production system, installed in late December 2021, is now operational at its headquarters site in Minnesota.

News for Calyxt Stock (CLXT)